Literature DB >> 20451566

Evaluation of real-time PCR targeting hbb gene for Borrelia species identification.

Jana Ferdin1, Tjasa Cerar, Franc Strle, Eva Ruzić-Sabljić.   

Abstract

Several molecular methods have been employed for Borrelia species identification. Newly developed technology, real-time polymerase chain reaction (RT-PCR), combines simultaneous amplification, detection and differentiation of strains in one PCR run. The aim of the study was to perform and evaluate RT-PCR for Borreliaburgdorferi sensu lato species identification. Borrelia species identification was accomplished on 374 Borrelia strains using two approaches: 1.) MluI restriction of entire borrelial chromosome (MluI-large restriction fragment patterns, LRFP), and 2.) RT-PCR targeting hbb gene and specific melting temperature (Tm) detection. The results of the two molecular methods were compared. With MluI-RFLP we were able to differentiate all Borrelia species and their subtypes within particular species. RT-PCR based on Tm determination identified unique strains within the species Borreliaafzelii (Tm 66.11 degrees C), B. burgdorferi sensu stricto (Tm 68.18 degrees C), Borreliaspielmanii (Tm 59.45 degrees C) and Borreliavalaisiana (Tm 59.62 degrees C). We were not able to distinguish the last two species that shared almost identical Tm. The large majority of Borreliagarinii strains shared Tm 51.42 degrees C, while subtype Mlg4 was characterized by Tm 56.87 degrees C. Strains of Borrelialusitaniae species also were heterogeneous; human isolate had Tm 63.47 degrees C while two tick isolates shared Tm 61.77 degrees C. Differences inside hbb gene enabled differentiation of the majority of Borrelia species, and revealed two clusters within B. garinii and B. lusitaniae species, respectively, but it was not possible to distinguish B. spielmanii form B. valaisiana. The major advantage of RT-PCR was that it was easy to perform and that the results were obtained within a few hours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451566     DOI: 10.1016/j.mimet.2010.04.009

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  6 in total

1.  Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis.

Authors:  Daša Stupica; Vera Maraspin; Petra Bogovic; Katarina Ogrinc; Rok Blagus; Tjaša Cerar; Franc Strle
Journal:  JAMA Dermatol       Date:  2018-09-01       Impact factor: 10.282

2.  Immunohistochemistry and real-time PCR as diagnostic tools for detection of Borrelia burgdorferi sensu lato in ticks collected from humans.

Authors:  Violeta T Briciu; Daniela Sebah; Georgiana Coroiu; Mihaela Lupşe; Dumitru Cârstina; Doina F Ţăţulescu; Andrei D Mihalca; Călin M Gherman; Daniel Leucuţa; Fabian Meyer; Cecilia Hizo-Teufel; Volker Fingerle; Ingrid Huber
Journal:  Exp Appl Acarol       Date:  2016-01-22       Impact factor: 2.132

3.  A new real-time PCR protocol for detection of avian haemosporidians.

Authors:  Jeffrey A Bell; Jason D Weckstein; Alan Fecchio; Vasyl V Tkach
Journal:  Parasit Vectors       Date:  2015-07-19       Impact factor: 3.876

4.  Sensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti.

Authors:  Kamfai Chan; Salvatore A E Marras; Nikhat Parveen
Journal:  BMC Microbiol       Date:  2013-12-20       Impact factor: 3.605

5.  Clinical Course, Serologic Response, and Long-Term Outcome in Elderly Patients with Early Lyme Borreliosis.

Authors:  Katarina Boršič; Rok Blagus; Tjaša Cerar; Franc Strle; Daša Stupica
Journal:  J Clin Med       Date:  2018-12-02       Impact factor: 4.241

6.  Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans.

Authors:  Daša Stupica; Fajko F Bajrović; Rok Blagus; Tjaša Cerar Kišek; Stefan Collinet-Adler; Eva Ružić-Sabljić; Maša Velušček
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.